UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Faculty Profiles

Paula Lum, MD, MPH
M_MED-AIDS-ZSFG
Professor

1001 Potrero Ave
San Francisco, CA 94110
415-476-4082 ext. 411
Paula.Lum@ucsf.edu

Paula J. Lum, MD MPH is a Professor of Clinical Medicine at the University of California, San Francisco. She has been an Attending Physician in the HIV, ID and Global Medicine Division at San Francisco General Hospital since 1999 and is the Program Director of the UCSF Primary Care Addiction Medicine Fellowship. Board certified in internal medicine and addiction medicine, Dr. Lum practices at the place where HIV, addiction, and poverty collide. Her research and clinical activities are grounded in evidence-based, patient-centered care to improve the health outcomes and life quality of the urban poor. Her current areas of focus include: (1) HIV and viral hepatitis prevention and treatment in people who inject drugs, (2) evidence-based interventions for substance use disorders and their complications in primary care and non-traditional settings, and (3) curricular interventions to provide health care professionals with the skills, knowledge, and confidence to offer effective patient-centered care to persons who use drugs.

Education and Training

Location Degree or Training Specialty Date
University of California, San Francisco Postdoctoral studies Center for AIDS Prevention Studies 1999
University of California, Berkeley M.P.H. Epidemiology 1997
University of California, San Francisco Residency Primary Care Internal Medicine at SFGH 1996
Case Western Reserve University M.D. School of Medicine 1993
Stanford University M.A. Sociology 1985
Stanford University B.A. Human Biology 1985

Related Web Sites

Recent Articles (52)

Simeone C, Shapiro B, Lum PJ. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. Addict Sci Clin Pract. 2017 Aug 22; 12(1):19.

Kalkhoran S, Alvarado N, Vijayaraghavan M, Lum PJ, Yuan P, Satterfield JM. Patterns of and reasons for electronic cigarette use in primary care patients. J Gen Intern Med. 2017 Jul 14.

Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy. 2017 Jul; 45:64-69.

Vijayaraghavan M, Yuan P, Gregorich S, Lum P, Appelle N, Napoles AM, Kalkhoran S, Satterfield J. Disparities in receipt of 5As for smoking cessation in diverse primary care and HIV clinics. Prev Med Rep. 2017 Jun; 6:80-87.

Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sorensen JL, Arenas V, Ha D, Mandler RN, McCarty D. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017 Jun; 112(6):1036-1044.

Ahamad K, Korthuis PT, Lum PJ, Johnson C, Wood E. A delayed injection-site reaction in a patient receiving extended-release naltrexone. Subst Abus. 2016 Apr-Jun; 37(2):278-80.

Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, Page K. A Longitudinal Study of Multiple Drug Use and Overdose Among Young People Who Inject Drugs. Am J Public Health. 2016 May; 106(5):915-7.

Dawson-Rose C, Draughon JE, Zepf R, Cuca YP, Huang E, Freeborn K, Lum PJ. Prevalence of Substance Use in an HIV Primary Care Safety Net Clinic: A Call for Screening. J Assoc Nurses AIDS Care. 2017 Mar - Apr; 28(2):238-249.

Kalkhoran S, Appelle NA, Napoles AM, Munoz RF, Lum PJ, Alvarado N, Gregorich SE, Satterfield JM. Beyond the Ask and Advise: Implementation of a Computer Tablet Intervention to Enhance Provider Adherence to the 5As for Smoking Cessation. J Subst Abuse Treat. 2016 Jan; 60:91-100.

Dawson Rose C, Cuca YP, Kamitani E, Eng S, Zepf R, Draughon J, Lum P. Using Interactive Web-Based Screening, Brief Intervention and Referral to Treatment in an Urban, Safety-Net HIV Clinic. AIDS Behav. 2015 Jun; 19 Suppl 2:186-93.

Whittle AE, Buckelew SM, Satterfield JM, Lum PJ, O'Sullivan P. Addressing Adolescent Substance Use: Teaching Screening, Brief Intervention, and Referral to Treatment (SBIRT) and Motivational Interviewing (MI) to Residents. Subst Abus. 2015; 36(3):325-31.

Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014 Dec; 174(12):1974-81.

Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceño A, Morris MD, Lum PJ, Page K. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014 May 29; 4(5):e004988.

Ratanawongsa N, Barton JL, Schillinger D, Yelin EH, Hettema JE, Lum PJ. Ethnically diverse patients' perceptions of clinician computer use in a safety-net clinic. J Health Care Poor Underserved. 2013 Nov; 24(4):1542-51.

McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr; 23(2):137-44.

Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013 Nov-Dec; 12(6):375-7.

McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med. 2013 Jul-Aug; 7(4):264-70.

Manuel JK, Lum PJ, Hengl NS, Sorensen JL. Smoking cessation interventions with female smokers living with HIV/AIDS: a randomized pilot study of motivational interviewing. AIDS Care. 2013; 25(7):820-7.

Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, Delwart E, Tobler L, Cox AL, Busch MP. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis. 2013 Feb; 56(3):405-13.

McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. Untreated HIV infection is associated with higher blood alcohol levels. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):282-8.

Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012 Feb 15; 175(4):302-8.

Hettema JE, Ratanawongsa N, Manuel JK, Ciccarone D, Coffa D, Jain S, Lum PJ. A SBIRT curriculum for medical residents: development of a performance feedback tool to build learner confidence. Subst Abus. 2012; 33(3):241-50.

Johnson MO, Dilworth SE, Stephens E, Lum PJ, Neilands TB. Expectancy and readiness-based predictors of treatment uptake among the urban poor living with HIV. J Acquir Immune Defic Syndr. 2011 Dec 15; 58(5):469-71.

Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011 Aug 02; 11:208.

Asher A, Lum PJ, Page K. Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report. J Assoc Nurses AIDS Care. 2012 Jan-Feb; 23(1):16-29.

Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S83-90.

Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S33-8.

Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S22-32.

Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, Fiellin DA. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S54-61.

Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, Fiellin DA. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S91-7.

Etcheverry MF, Lum PJ, Evans JL, Sanchez E, de Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011 Feb 24; 29(10):1991-6.

Rose CD, Courtenay-Quirk C, Knight K, Shade SB, Vittinghoff E, Gomez C, Lum PJ, Bacon O, Colfax G. HIV intervention for providers study: a randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):572-81.

Levy V, Evans JL, Stein ES, Davidson PJ, Lum PJ, Hahn JA, Page K. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine. 2010 Aug 23; 28(37):5947-51.

Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010 Jul; 105(7):1254-64.

Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch MP. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009 Oct 15; 200(8):1216-26.

Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend. 2009 May 01; 101(3):152-7.

Inglez-Dias A, Hahn JA, Lum PJ, Evans J, Davidson P, Page-Shafer K. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. Drug Alcohol Rev. 2008 May; 27(3):286-91.

Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat. 2008 Mar; 15(3):229-36.

Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend. 2008 Jan 11; 93(1-2):43-50.

Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS. 2007 Sep 12; 21(14):1967-9.

Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007 Jan 11; 21(2):239-41.

Lum PJ, Tulsky JP. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep. 2006 Nov; 3(4):195-204.

Bacon O, Lum P, Hahn J, Evans J, Davidson P, Moss A, Page-Shafer K. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Sex Transm Dis. 2006 Apr; 33(4):228-34.

Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 01; 41(1):31-6.

Lum PJ, Sears C, Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse. 2005; 40(11):1681-96.

Lum PJ, Ochoa KC, Hahn JA, Page Shafer K, Evans JL, Moss AR. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am J Public Health. 2003 Jun; 93(6):919-23.

Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, Moss AR. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003 Mar; 80(1):137-46.

Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr. 2002 Dec 01; 31(4):422-31.

Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002 Dec 01; 186(11):1558-64.

Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001 Jul; 34(1):180-7.

Sears C, Guydish JR, Weltzien EK, Lum PJ. Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A. J Acquir Immune Defic Syndr. 2001 Jun 01; 27(2):193-201.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.